Skip to Content
Merck
  • An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor.

An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor.

Chest (2013-05-08)
Nicholas G Wysham, Donald R Sullivan, Gopal Allada
ABSTRACT

We report a case of Cryptococcus neoformans pneumonia in a patient taking ruxolitinib, a janus kinase 1,2 inhibitor approved for the treatment of myelofibrosis. We hypothesize that ruxolitinib contributed to this infection through its effects on cell-mediated immunity. Clinicians should be aware of the potential for intracellular or opportunistic infections associated with this novel drug class.

MATERIALS
Product Number
Brand
Product Description

Supelco
Fluconazole, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Fluconazole, ≥98% (HPLC), powder
Fluconazole, European Pharmacopoeia (EP) Reference Standard
Fluconazole for peak identification, European Pharmacopoeia (EP) Reference Standard